Rediscovering women’s health

Women’s health is entering a pivotal moment. After decades of underrepresentation in research and funding, innovation is finally catching up—driven by landmark studies, new policy initiatives, and a surge of dedicated biotechs addressing long-neglected conditions.

The momentum is clear:

• Global funding commitments exceeding $2.5bn through 2030, including major initiatives from the Gates Foundation
• Women-focused R&D expanding beyond reproductive health into cardiovascular, neurological, and inflammatory diseases
• A new generation of companies rethinking fertility, menopause, endometriosis, and maternal health with hormone-free, microbiome-based, and precision approaches

Our report spotlights leading innovators transforming care for half the world’s population—including Daré Bioscience, Freya Biosciences, Gesynta Pharma, Granata Bio, and Oxolife.

What’s inside the report?

• Funding and deal intelligence: Who’s investing and partnering in women’s health innovation
• Clinical and pipeline insights: Programs advancing beyond reproductive health into broader chronic disease areas
• Company profiles: Emerging biotechs leveraging novel mechanisms—from microbial immunotherapies to next-generation non-hormonal therapeutics
• Market outlook: How governments, investors, and pharma are reshaping the global women’s health ecosystem

Built using proprietary data and insights from the BioWorld and Clarivate Cortellis suite — including Clinical Trials Intelligence, Deals Intelligence, Competitive Intelligence, and Regulatory Intelligence — this report delivers a data-driven view of the companies redefining the future of women’s health innovation.